Natural Resources committee  Let me start by answering the Nordion question. As I said to Mr. Hyer, we don't comment publicly about the status of our contracts and relationships, so unfortunately I can't do that in this forum. But I'd like to turn things over to Cyrille to talk about how we would allocate those materials to the Canadian customers, and how we really think about equity as it applies to the Canadian market when we have supply of molybdenum-99.

Natural Resources committee  I think the F18-labelled products will change things very significantly. They will facilitate a change in the overall manufacturing logistics associated with these diagnostic imaging products. We'll see ourselves moving from an environment where we're sourcing as much material today from the reactors, to an environment where perhaps we're sourcing less material from reactors.

Natural Resources committee  Thank you. Maybe to sum it all up, we don't really disclose the information specific to our contracts. But as it applies to the Canadian customer and patients, ultimately we're working to diversify our supply chain and establish the best approach to supply all of North America in an equitable fashion.

Natural Resources committee  Let me start with the where and with a kind of timeframe for production. I think many who have studied this topic are familiar with the global supply chain. There are global suppliers of molybdenum around the world. These are the reactor producers or reactor-based suppliers. They include Nordion, through their relationship with AECL in Canada; IRE, through their relationship with three reactors in Europe; and Covidien, through their relationship with a number of reactors in Europe.